BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24499951)

  • 1. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
    Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
    AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
    BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
    Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
    Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
    PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
    Were EO; Heffron R; Mugo NR; Celum C; Mujugira A; Bukusi EA; Baeten JM;
    AIDS; 2014 Aug; 28(13):1977-82. PubMed ID: 25259704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC; Kebaabetswe PM; Paxton LA; Smith DK; Rose CE; Segolodi TM; Henderson FL; Pathak SR; Soud FA; Chillag KL; Mutanhaurwa R; Chirwa LI; Kasonde M; Abebe D; Buliva E; Gvetadze RJ; Johnson S; Sukalac T; Thomas VT; Hart C; Johnson JA; Malotte CK; Hendrix CW; Brooks JT;
    N Engl J Med; 2012 Aug; 367(5):423-34. PubMed ID: 22784038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
    J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
    N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
    Grant RM; Lama JR; Anderson PL; McMahan V; Liu AY; Vargas L; Goicochea P; Casapía M; Guanira-Carranza JV; Ramirez-Cardich ME; Montoya-Herrera O; Fernández T; Veloso VG; Buchbinder SP; Chariyalertsak S; Schechter M; Bekker LG; Mayer KH; Kallás EG; Amico KR; Mulligan K; Bushman LR; Hance RJ; Ganoza C; Defechereux P; Postle B; Wang F; McConnell JJ; Zheng JH; Lee J; Rooney JF; Jaffe HS; Martinez AI; Burns DN; Glidden DV;
    N Engl J Med; 2010 Dec; 363(27):2587-99. PubMed ID: 21091279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.